Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies?

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 882-884

  Hernandez Gea, Virginia ^a   Alsinet, Clara ^a   Llovet, Josep M ^a,b,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Hepatocellular carcinoma; Immunotherapy; Oncolytic virus

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEXASTIMOGENE DEVACIREPVEC; SORAFENIB;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DISEASE CONTROL; DRUG MECHANISM; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; MOLECULAR THERAPY; NOTE; PRIORITY JOURNAL; RADIOLOGIST; TREATMENT RESPONSE; VIRUS REPLICATION;

HEPATOCELLULAR CARCINOMA; IMMUNOTHERAPY; ONCOLYTIC VIRUS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS;

EID: 84884412588     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.05.006     Document Type: Note

References (12)

1. R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, and V. Aboyans Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
2. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
3. J.M. Llovet, C. Pena, C. Lathia, M. Shan, G. Meinhardt, and J. Bruix Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2290 2300
4. A. Villanueva, V. Hernandez-Gea, and J.M. Llovet Medical therapies for hepatocellular carcinoma: a critical view of the evidence Nat Rev Gastroenterol Hepatol 10 2013 34 42
5. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL, EORTC EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
6. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
7. C.J. Breitbach, J. Burke, D. Jonker, J. Stephenson, A.R. Haas, and L.Q. Chow Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Nature 477 2011 99 102
8. C.J. Breitbach, R. Arulanandam, N. De Silva, S.H. Thorne, R. Patt, and M. Daneshmand Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans Cancer Res 73 2012 1 11
9. S. Faivre, E. Raymond, E. Boucher, J. Douillard, H.Y. Lim, and J.S. Kim Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
10. J.M. Llovet, T. Decaens, J.-L. Raoul, E. Boucher, M. Kudo, and C. Chang Brivanib versus placebo in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: results from the phase III BRISK-PS study J Hepatol 56 2012 S549
11. D.F. Calvisi, S. Ladu, A. Gorden, M. Farina, E.A. Conner, and J.S. Lee Ubiquitous activation of Ras and Jak/Stat pathways in human HCC Gastroenterology 130 2006 1117 1128
12. P. Newell, S. Toffanin, A. Villanueva, D.Y. Chiang, B. Minguez, and L. Cabellos Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo J Hepatol 51 2009 725 733